Eupraxia Pharmaceuticals ... (EPRX)
3.50
-0.31 (-8.14%)
At close: Mar 04, 2025, 10:55 AM
Eupraxia Pharmaceuticals Cash Flow Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Net Income | -37.39M | -23.92M | -23.37M | -4.01M | -7.24M | -14.83M | -5M |
| Depreciation & Amortization | 209.91K | 193.27K | 111.53K | 116.81K | 201.94K | 125.83K | 85.38K |
| Stock-Based Compensation | 1.41M | 1.43M | 4.21M | 228.68K | 544.95K | 2.92M | 162.82K |
| Other Working Capital | 6.47M | 1.76M | -402.32K | 832.37K | 346.87K | 1.31M | -259.17K |
| Other Non-Cash Items | 1.53M | 1.16M | 3.41M | 1.69M | 869.41K | 2.08M | 51.17K |
| Deferred Income Tax | n/a | -305.15K | 1.2M | 10.91K | -28.86K | 291.05K | n/a |
| Change in Working Capital | 6.33M | 2.07M | -211.43K | 1.56M | 482.14K | 1.1M | -599.39K |
| Operating Cash Flow | -27.92M | -18.78M | -14.64M | -403.93K | -5.17M | -8.32M | -5.3M |
| Capital Expenditures | -73.38K | -308.37K | -431.67K | n/a | -9.48K | -141.86K | -314.69K |
| Acquisitions | n/a | 310.00 | n/a | 81.31K | n/a | n/a | n/a |
| Purchase of Investments | n/a | -310 | -9M | n/a | n/a | n/a | n/a |
| Sales Maturities Of Investments | n/a | 9.01M | n/a | n/a | n/a | n/a | n/a |
| Other Investing Acitivies | -1.81K | 310.00 | -5.02M | -56.69K | -1.89M | n/a | n/a |
| Investing Cash Flow | -99.03K | 8.7M | -14.45M | 24.62K | -1.9M | -141.86K | -314.69K |
| Debt Repayment | -144.44K | -97.49K | 12.17M | -525.95K | 5.66M | 2.67M | 463.06K |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 12.1M | 2.98M | 8.07M | -100.69K | 1.73M | 2.62M | 1.81M |
| Financial Cash Flow | 27.84M | 13.52M | 49.92M | -626.64K | 7.4M | 5.3M | 9.47M |
| Net Cash Flow | 1.08M | 3.84M | 20.74M | -1.01M | 332.6K | -3.17M | 3.85M |
| Free Cash Flow | -28.02M | -19.08M | -15.07M | -403.93K | -5.18M | -8.46M | -5.61M |